Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
Takao Takahashi(Maruyama Memorial General Hospital), Yoshihiko Maehara(Kyushu University), Hiroyuki Uetake(National Hospital Organization), Naohiro Tomita(Toyonaka Municipal Hospital), Eiji Oki(Kyushu University), Yasunori Emi(Saiseikai Fukuoka General Hospital), Kei Muro(Aichi Cancer Center), Kazuhiro Yoshida(Kyoto Institute of Technology), Johji Imura(Saitama Prefectural Kumagaya Girls High School), Michiaki Unno(Tohoku University), Shinichi Aishima(Saga University), Michiie Sakamoto(Keio University), Kenichi Sugihara(Toujinkai Hospital), Yu Katayose(Tohoku Medical and Pharmaceutical University), Ichinosuke Hyodo(Shikoku Cancer Center), Kazuyuki Ishida(Tokyo Medical and Dental University)
Cited by 4
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k